[{"orgOrder":0,"company":"DAAN Biotherapeutics","sponsor":"Ligachem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"DAAN Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"DAAN Biotherapeutics \/ LigaChem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"DAAN Biotherapeutics \/ LigaChem Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by DAAN Biotherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : Under the licensing agreement, LigaChem will leverage DAAN Biotherapeutics' next-generation antibody technology for the treatment of solid tumor patients.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          February 13, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Ligachem Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank